There is an increased risk of bleeding when patients taking anticoagulant or antiplatelet drugs require surgery. This risk must be balanced against the risk of harm if treatment is stopped. For many minor procedures aspirin or warfarin can be continued. patients having non-cardiac surgery may be able to continue aspirin, but clopidogrel should be stopped unless there is a high risk of thrombosis. patients taking warfarin may require bridging anticoagulation around the time of major surgery. This involves replacing the warfarin with unfractionated or low molecular weight heparin. Consultation with a cardiologist is particularly recommended if a patient with a coronary stent requires surgery.
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Antiplatelet therapy
Aspirin irreversibly inhibits platelet function via the acetylation of cyclo-oxygenase-1. Clopidogrel, a thienopyridine, selectively inhibits adenosine diphosphate-induced platelet aggregation. 1 The effect of both drugs lasts for the lifespan of the platelet (approximately 7-10 days). Although it seems logical to stop either drug 7-10 days before an elective procedure, platelet function is only one of the many important mechanisms of coagulation necessary for adequate haemostasis. Aspirin can be continued for most procedures but whether or not clopidogrel can be safely continued depends on the risk of recurrent thrombosis versus bleeding.
Risk of perioperative bleeding
Clinical studies have shown that patients who have taken aspirin preoperatively have an increased risk of postoperative bleeding after cardiac and non-cardiac surgery. Use of aspirin within seven days of coronary artery bypass grafting has been associated with increased blood loss and the need for re-operation, but this does not increase mortality. 1 However, another study showed that aspirin use in the five days before coronary artery bypass grafting was associated with a lower risk of postoperative mortality, without a concomitant increase in re-operation for bleeding or the need for blood transfusion. 2 This applied to a range of aspirin doses, 100 mg to 975 mg daily.
It is generally considered safe to continue aspirin throughout the perioperative period, for both cardiac and non-cardiac surgery, unless there is a significant bleeding risk (Fig. 1) .
The use of clopidogrel throughout the perioperative period is more controversial. Some studies have shown an increased risk of major bleeding with the use of clopidogrel within five days of coronary artery bypass grafting. 3 While recognising the increased risk of bleeding complications after coronary artery bypass grafting, some experts recommend a more tailored approach depending on individual risk with respect to ischaemic complications and bleeding. 4 For percutaneous coronary intervention, pretreatment with clopidogrel is recommended before and throughout the perioperative period.
Patients with coronary stents in situ have a high thrombotic risk if antiplatelet drug therapy is interrupted. Elective non-cardiac surgery should therefore be avoided after stent placement when patients are most prone to thrombosis. This is during the first six weeks for bare metal stents, and during the first 12 months for drug-eluting stents. 5 For patients without coronary stents who are not at high risk of cardiac events, clopidogrel can be ceased 5-7 days before surgery. 5 It is often routine clinical practice to consult the patient's cardiologist before stopping the drug. Clopidogrel should be resumed following the procedure as soon as there is adequate haemostasis, usually the morning after surgery. 
Stopping heparin preoperatively
For patients who receive bridging anticoagulation with therapeutic doses of low molecular weight heparin, the last dose should be administered at least 24 hours before the procedure. There is evidence suggesting that there will be a residual anticoagulant effect if low molecular weight heparin is given too close to the time of the procedure. 6 It is recommended 
Fig. 2 perioperative management of patients receiving warfarin for atrial fibrillation, venous thromboembolism or mechanical heart valves
Warfarin can be resumed on the evening of the procedure. LMWH or UFH can be resumed 12-72 hours following the procedure, depending on the type of surgery.
The initial dose will vary from prophylactic dose (for example enoxaparin 40 mg daily) to therapeutic dose (for example enoxaparin 1 mg/kg twice daily) depending on the risk of thrombosis.
LMWH Low molecular weight heparin UFH Unfractionated heparin Low High
Bridge with therapeutic doses of LMWH or UFH.
Last LMWH dose to be administered 24 hours before surgery, stop UFH infusion 4-6 hours prior.
Prophylactic dose LMWH or no bridging
Pre-surgery or procedure Post-surgery or procedure Assess risk of thromboembolism that the last preoperative dose be half the usual total daily dose. 5 For unfractionated heparin, it is recommended that the infusion be stopped 4-6 hours before the procedure.
Resuming heparin postoperatively
The factors that affect the risk of postoperative bleeding include the timing of the anticoagulant dose after surgery, the dose of anticoagulant and the type of surgery along with its associated bleeding risk. 5, 7, 8 The following recommendations take all of these factors into consideration: ■ ■ warfarin can be resumed on the evening of the procedure (regardless of whether the procedure is performed in the morning or afternoon), at the usual maintenance dose (no loading dose) ■ ■ low molecular weight heparin or unfractionated heparin can be resumed 12-24 hours following the procedure for minor surgery. For major surgery, the first dose should be 24-72 hours post surgery. 9 The initial dose will vary from the prophylactic dose (for example, enoxaparin 40 mg daily) to the therapeutic dose (for example, enoxaparin 1 mg/kg twice daily) depending on the risk of thrombosis, and the risk of bleeding. This needs to be individualised for each patient.
epidural or spinal anaesthesia
In patients receiving bridging anticoagulation with heparin, the last dose of low molecular weight heparin should be given 24 hours before, and unfractionated heparin should be stopped four to six hours before the insertion or removal of the epidural or spinal needle. The procedure should be performed by an experienced anaesthetist. It is preferable to not give therapeutic doses of low molecular weight heparin with catheter in situ and to wait at least one hour after removing the catheter before recommencing intravenous unfractionated heparin.
Dental, dermatological or ophthalmological procedures
It is usually safe to continue aspirin around the time of the procedure. However, clopidogrel should be stopped 5-7 days before the procedure unless the patient has had a recent stent insertion. 5 Warfarin can usually be continued in patients having minor dental procedures (single or multiple tooth extraction and root canal procedures), minor dermatological procedures 
other anticoagulant drugs
There are an increasing number of patients participating in clinical trials that evaluate the efficacy and safety of other oral anticoagulants such as rivaroxaban and dabigatran for the treatment and prevention of venous and arterial thrombosis.
Rivaroxaban, a direct factor Xa inhibitor, has a half-life of 4-9 hours. Dabigatran has a longer half-life of 14-17 hours. 12 Bridging anticoagulation with a heparin can be used if indicated.
This can be started 24 hours after the last dose of rivaroxaban or dabigatran.
Conclusion
The 
